Guam reports four new Covid deaths
By Pacific Island Times News Staff
The Joint Information Center reported four new Covid-19 related fatalities, including a breakthrough death.
The 239th fatality occurred at the Guam Regional Medical City on Oct. 29. The patient was a 78-year-old female, unvaccinated, with underlying health conditions. She tested positive on Oct. 22.
The 240th fatality occurred at the Guam Memorial Hospital (GMH) on Oct. 30. The patient was a 46-year-old male, vaccinated, with unknown underlying health conditions. He tested positive on Oct. 29.
The 241st fatality occurred at GMH on Oct. 31. The patient was a 63-year-old female, unvaccinated, with unknown underlying health conditions. She tested positive on Oct. 28.
The 242nd patient was pronounced dead on arrival at the U.S. Naval Hospital Guam on Oct. 31. The patient was a 95-year-old female, unvaccinated, with underlying health conditions. She tested positive on Oct. 20.
Today, the Department of Public Health and Social Services (DPHSS) reported 13 new cases of Covid-19 out of 155 tests performed on Oct. 31.
An additional 65 cases were also reported today as a result of complete analysis and case submissions from other clinics for preliminary Covid-19 test results reported Oct. 30 – 31.
To date, there have been a total of 18,286 officially reported cases, 242 deaths, 2,312 cases in active isolation, and 15,732 not in active isolation. The CAR Score is 15.7.
There are 53 currently in hospitals, including one pediatric case, nine in ICU and six on ventilators.
To date, a total of 123,866 of Guam’s eligible population (residents 12 years and older) is fully vaccinated. This percentage includes 12,052 fully vaccinated residents between the ages of 12 – 17, and 111,814 fully vaccinated adults. 10,467 doses of the Pfizer-BioNTech vaccine have been administered to eligible residents as either a booster or an additional dose. 3,135 doses of the Moderna vaccine have been administered as either a booster or an additional dose to eligible residents. 81 doses of the Johnson and Johnson/Janssen vaccine have been administered as either a booster or as an additional dose to eligible residents.